Chad Robins
Co-Founder, Chief Executive Officer, Chairman, Adaptive Biotechnologies
Chad Robins is the chief executive officer and co-founder of Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Since its founding in 2009, Chad has led Adaptive in building a proprietary immune medicine platform that fuels businesses across life sciences research, clinical diagnostics, and drug discovery. Chad is actively engaged in the biotech and health policy communities, serving on the executive board of Life Science Washington and the steering committee of the Coalition for 21st Century Medicine. In addition to serving as Chairman of the Board for Adaptive, he also holds board positions with AltPep, AdvaMedDx, and HeadLight. Chad graduated with honors from Cornell University and obtained his MBA from The Wharton School at the University of Pennsylvania. Prior to Adaptive, Chad held executive-level positions in real estate, investment banking, private equity, and medical technology.
